Luteinizing hormone-releasing hormone antagonists [PDF]
Expert Opinion on Therapeutic Patents, 2009 Luteinizing hormone-releasing hormone (LH-RH) plays a central role in the vertebrate reproduction by regulating gonadal activity. Based on its binding to pituitary LH-RH receptors, as well as to LH-RH receptors expressed on cancer cells, LH-RH agonists and antagonists have been developed for different therapeutic applications.Here we give an overview ...
Mezö, Gábor, Manea, Marilena
openaire +3 more sources
Growth Hormone Receptor Antagonists [PDF]
The Journal of Clinical Endocrinology & Metabolism, 2004 Pegvisomant is the only member of a new class of drugs that was especially designed to block the GH receptor (GHR) and, therefore, GH action. In this review we will describe the structure and function of GH and its receptor with specific relevance to the discovery and development of GHR antagonists.
Müller, A.F. +3 more
openaire +2 more sources
Recent Development of Non-Peptide GnRH Antagonists
Molecules, 2017 The decapeptide gonadotropin-releasing hormone, also referred to as luteinizing hormone-releasing hormone with the sequence (pGlu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH2) plays an important role in regulating the reproductive system.
Feng-Ling Tukun +5 more
doaj +1 more source
Synergistic drug combinations from electronic health records and gene expression. [PDF]
, 2016 ObjectiveUsing electronic health records (EHRs) and biomolecular data, we sought to discover drug pairs with synergistic repurposing potential. EHRs provide real-world treatment and outcome patterns, while complementary biomolecular data, including ...
Chen, William +19 more
core +2 more sources
Preparation and Characterization of an Antibody Antagonist That Targets the Porcine Growth Hormone Receptor [PDF]
Asian-Australasian Journal of Animal Sciences, 2016 A series of antagonists specifically targeting growth hormone receptors (GHR) in different species, such as humans, rats, bovines, and mice, have been designed; however, there are currently no antagonists that target the porcine growth hormone (GH ...
Huanzhong Cui +3 more
doaj +1 more source
A meta-analysis and systematic review of randomized controlled trials with degarelix versus gonadotropin-releasing hormone agonists for advanced prostate cancer [PDF]
, 2016 Our aim was to systematically evaluate the benefits of degarelix as antagonist versus agonists of gonadotropin-releasing hormones (GnRH) for the treatment of advanced prostate cancer (PC).
CATTARINO, SUSANNA +10 more
core +1 more source
A selective alpha1D-adrenoreceptor antagonist inhibits human prostate cancer cell proliferation and motility "in vitro" [PDF]
, 2016 The progression of prostate cancer (PC) to a metastatic hormone refractory disease is the major contributor to the overall cancer mortality in men, mainly because the conventional therapies are generally ineffective at this stage. Thus, other therapeutic
Bolchi, Cristiano +8 more
core +2 more sources
The androgen receptor and signal-transduction pathways in hormone-refractory prostate cancer. Part 1: modifications to the androgen receptor [PDF]
, 2005 Prostate cancer is the second most common male malignancy in the western world an increasing incidence in an ageing population. Treatment of advanced prostate cancer relies on androgen deprivation.
Bakin RE +7 more
core +1 more source
Gonadotropin-releasing hormone analogs: Understanding advantages and limitations
Journal of Human Reproductive Sciences, 2014 Pituitary stimulation with pulsatile gonadotropin-releasing hormone (GnRH) analogs induces both follicle-stimulating hormone (FSH) and luteinizing hormone (LH).
Pratap Kumar, Alok Sharma
doaj +1 more source